A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research
- PMID: 23651763
- PMCID: PMC4450361
- DOI: 10.1016/j.jclinepi.2013.02.009
A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research
Abstract
Individuals vary in their response to a treatment. Understanding this heterogeneity of treatment effect is critical for evaluating how well a treatment can be expected to work for an individual or a subgroup of individuals. An overemphasis on hypothesis testing has resulted in a dichotomy of all heterogeneity of treatment effect analyses into confirmatory (hypothesis testing) and exploratory (hypothesis finding) analyses. This limited view of heterogeneity of treatment effect is inadequate for creating evidence that is useful for informing patient-centered decisions. An expanded framework for heterogeneity of treatment effect assessment is proposed. It recognizes four distinct goals of heterogeneity of treatment effect analyses: hypothesis testing, hypothesis finding, reporting subgroup effects for meta-analysis, and individual-level prediction. Accordingly, two new types of heterogeneity of treatment effect analyses are proposed: descriptive and predictive. Descriptive heterogeneity of treatment effect analyses report treatment effects for prespecified subgroups in accordance with prospectively specified analytic strategy. They need not be powered to detect heterogeneity of treatment effect. They emphasize estimation and reporting of subgroup effects rather than hypothesis testing. Sampling properties (e.g., standard error) of descriptive analysis can be characterized, thus facilitating meta-analysis of subgroup effects. Predictive heterogeneity of treatment effect analyses estimate probabilities of beneficial and adverse responses of individuals to treatments and facilitates optimal treatment decisions for different types of individuals. Procedures are also suggested to improve reliability of heterogeneity of treatment effect assessment from observational studies. Heterogeneity of treatment effect analysis should be identified as confirmatory, descriptive, exploratory, or predictive analysis. Evidence should be interpreted in a manner consistent with the analytic goal.
Copyright © 2013 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest: None of the authors have any relevant financial interests or other conflicts to disclose.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.Health Technol Assess. 2001;5(33):1-56. doi: 10.3310/hta5330. Health Technol Assess. 2001. PMID: 11701102 Review.
-
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. Report No.: 21-05274-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. Report No.: 21-05274-EF-1. PMID: 34644040 Free Books & Documents. Review.
-
Behavioral Counseling Interventions to Prevent Sexually Transmitted Infections: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Aug. Report No.: 19-05260-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Aug. Report No.: 19-05260-EF-1. PMID: 32970399 Free Books & Documents. Review.
-
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer.BMC Med Res Methodol. 2012 Dec 13;12:185. doi: 10.1186/1471-2288-12-185. BMC Med Res Methodol. 2012. PMID: 23234603 Free PMC article. Review.
Cited by
-
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.Cancer. 2015 Jul 1;121(13):2147-55. doi: 10.1002/cncr.29332. Epub 2015 Mar 10. Cancer. 2015. PMID: 25757699 Free PMC article.
-
Precision Medicine and Heterogeneity of Treatment Effect in Therapies for ARDS.Chest. 2021 Nov;160(5):1729-1738. doi: 10.1016/j.chest.2021.07.009. Epub 2021 Jul 14. Chest. 2021. PMID: 34270967 Free PMC article. Review.
-
Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine.BMC Med. 2016 Dec 15;14(1):197. doi: 10.1186/s12916-016-0744-x. BMC Med. 2016. PMID: 27974045 Free PMC article.
-
A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases.NPJ Digit Med. 2023 Mar 30;6(1):58. doi: 10.1038/s41746-023-00794-y. NPJ Digit Med. 2023. PMID: 36991144 Free PMC article.
-
Regularized outcome weighted subgroup identification for differential treatment effects.Biometrics. 2015 Sep;71(3):645-53. doi: 10.1111/biom.12322. Epub 2015 May 11. Biometrics. 2015. PMID: 25962845 Free PMC article.
References
-
- Washington AE, Lipstein SH. The Patient-Centered Outcomes Research Instituted—promoting better information, decisions, and health. N Engl J Med. 2011;365:e31. - PubMed
-
- Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93–98. - PubMed
-
- Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–186. - PubMed
-
- Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–2194. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources